The Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls<\/strong> (commonly known by its acronym, SARC-F<\/a>) is a brief, clinician- and self-administered five-item screening tool designed to identify individuals at risk for sarcopenia and related adverse geriatric outcomes. Developed by Theodore K. Malmstrom and John E. Morley in 2013, the instrument operationalizes cardinal clinical manifestations of skeletal muscle failure: loss of gross muscle strength, impaired ambulation, lower-extremity transfer failure, stair-climbing limitation, and fall frequency. Each item is scored ordinally from 0 to 2, yielding a cumulative scale score ranging from 0 to 10, wherein a clinical cut-off score of 4 or higher indicates high risk for sarcopenia and warrants formal diagnostic evaluation involving muscle mass quantification and physical performance testing. Extensive psychometric evaluations across geriatric, community-dwelling, hospitalized, and oncological populations have established that while the SARC-F demonstrates moderate internal consistency (Cronbach’s α typically ranging between 0.65 and 0.81), it exhibits outstanding test-retest reliability (≥ 0.80) and a robust unidimensional or two-factor latent structure. Although its diagnostic sensitivity against international consensus operational criteria (such as EWGSOP2, AWGS 2019, and SDOC) is typically modest (20% to 50%), its high diagnostic specificity (frequently exceeding 85% to 95%) and profound negative predictive value render it an optimal public health and clinical triage mechanism. Critically, the instrument shows superior predictive validity for hard downstream endpoints, including incident frailty, emergency room visits, prolonged hospitalization, loss of activities of daily living (ADL) independence, and all-cause mortality, bridging psychological self-perception of functional capacity with biomarker-informed geriatric assessment<\/span>.<\/p>\n SARC-F, Sarcopenia screening, Muscle strength, Functional mobility, Geriatric assessment, Psychometrics, Fall risk, Frailty, Physical performance, Activities of daily living<\/p>\n The original SARC-F questionnaire was conceptualized and developed by:<\/p>\n Prominent international adaptation and validation researchers include:<\/p>\n The primary clinical and research objective of the Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls<\/strong> scale is to provide a rapid, inexpensive, non-invasive, and standardized screening mechanism for identifying individuals experiencing progressive loss of skeletal muscle function and mass. Sarcopenia<\/a> is officially recognized as a generalized and progressive skeletal muscle disorder under the International Classification of Diseases (ICD-10-CM code M62.84). Despite its profound association with loss of independence, institutionalization, and premature mortality, formal diagnostic algorithms requiring dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), or computed tomography (CT) are frequently inaccessible in primary care, home health, and low-resource settings.<\/p>\n The theoretical rationale behind the SARC-F is grounded in functional kinesiology and health-related self-efficacy: before objective muscle atrophy is formally quantified via radiologic imaging, individuals experience noticeable functional decrements during basic and instrumental activities of daily living that require lower-extremity power, mechanical leverage, and balance control. By quantifying self-reported difficulty across five physical tasks representing dynamic strength, stability, and biomechanical power, the SARC-F bridges biological tissue degradation and perceived disability. In clinical workflows, the tool serves as “Case Finding” (Step 1 of the EWGSOP2 and Asian Working Group for Sarcopenia [AWGS] diagnostic pathways), screening out low-risk populations while directing high-risk individuals toward targeted diagnostic confirmatory assessments (e.g., grip strength dynamometry, chair rise testing, and appendicular lean mass quantification) and early lifestyle or nutritional interventions.<\/p>\n The overarching construct quantified by the SARC-F is perceived functional limitation secondary to skeletal neuromuscular insufficiency<\/em>. This construct operates at the intersection of psychomotor capability, physical vulnerability, and self-appraisal of motor competence. Rather than measuring isolated maximum isometric force output in laboratory isolation, the scale assesses the patient’s ecological performance across five interconnected physical dimensions:<\/p>\n The SARC-F is theoretically anchored in the Disablement Process Model<\/strong> developed by Verbrugge and Jette (1994) and the World Health Organization’s International Classification of Functioning, Disability and Health (ICF)<\/strong>. Under the Disablement Process framework, human functional decline proceeds sequentially through four major domains: Pathology<\/em> (e.g., motor neuron loss, muscle protein catabolism, chronic inflammation), Impairments<\/em> (e.g., reduced maximum voluntary contraction, loss of Type II fast-twitch muscle fibers), Functional Limitations<\/em> (e.g., difficulty climbing stairs, slow walking speed, inability to rise from seated positions), and Disability<\/em> (e.g., inability to live independently or maintain social participation).<\/p>\n The SARC-F intentionally anchors its measurement layer directly at the Functional Limitations<\/em> level. Rather than asking respondents to introspectively estimate cellular muscle loss or abstract bioenergetic reserve, it evaluates the manifest behavioral consequences of motor unit denervation and muscle fiber atrophy on ecologically valid motor behaviors. Furthermore, Bandura’s Social Cognitive Theory<\/strong>, particularly the construct of perceived physical self-efficacy<\/em>, underpins the self-report mechanism: an individual’s subjective judgment of their capacity to execute physical tasks reflects integrated day-to-day somatic feedback, fear of falling, and biological neuromuscular fatigue, often detecting subclinical declines before catastrophic fall events occur.<\/p>\n Extensive international validation studies have evaluated the criterion, construct, convergent, discriminant, and predictive validity of the SARC-F across diverse geographic and clinical cohorts.<\/p>\n When evaluated against biological reference standards such as the European Working Group on Sarcopenia in Older People (EWGSOP, EWGSOP2) and the Asian Working Group for Sarcopenia (AWGS 2014, 2019), the SARC-F consistently demonstrates distinctive diagnostic characteristics:<\/p>\n The SARC-F exhibits strong, statistically significant negative correlations with objective physical performance metrics, including handgrip strength (dynamometry, r = -0.35 to -0.52, p < 0.001), 4-meter gait speed (r = -0.40 to -0.61, p < 0.001), and the Short Physical Performance Battery (SPPB; r = -0.55 to -0.71, p < 0.001). Conversely, it correlates positively with the Fried Frailty Phenotype score and the Clinical Frailty Scale (CFS). Discriminant validity has been demonstrated through its clear differentiation between robust community-dwelling older adults and institutionalized, post-stroke, or oncology cohorts suffering from cancer cachexia<\/span>.<\/p>\n The scale exhibits robust predictive validity for downstream adverse outcomes. In the African American Health (AAH) study, the Baltimore Longitudinal Study of Aging (BLSA), and the National Health and Nutrition Examination Survey (NHANES), a baseline SARC-F score ≥ 4 independently predicted 3-year incident loss of ADL independence (Adjusted Odds Ratio [AOR] = 2.5 to 3.8), incident physical disability (AOR = 3.2), increased hospitalization rates (Hazard Ratio [HR] = 1.6 to 2.1), and higher all-cause mortality (HR = 1.76 to 2.40, p < 0.01) after adjusting for age, sex, and comorbid medical conditions<\/span>.<\/p>\n The psychometric reliability of the SARC-F has been rigorously documented across multiple linguistic and cultural translations:<\/p>\n Structural evaluations using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA) have examined the internal structural validity of the SARC-F:<\/p>\n Principal axis factoring and principal component analysis across multiple validation samples typically yield a single dominant latent factor accounting for between 52% and 64% of the total variance, supporting the unidimensional clinical scoring paradigm (cumulative 0–10 score). Factor loadings across the physical performance items are uniformly high:<\/p>\n Item 5 (Falls) consistently displays lower, though statistically significant, communality and factor loading, reflecting the fact that falls are multifactorial events influenced by environmental hazards, orthostasis, and polypharmacy in addition to pure neuromuscular weakness.<\/p>\n In structural equation modeling (SEM) and CFA evaluations, a unidimensional model with correlated error terms between the highest-demand lower-extremity tasks (Climbing stairs and Rising from a chair) yields excellent model fit criteria:<\/p>\n Some psychometricians propose a two-factor model distinguishing between continuous Daily Motor Performance<\/em> (Items 1–4) and Episodic Postural Failure<\/em> (Item 5); however, because the correlation between these two latent dimensions exceeds r = 0.70, the parsimonious single-factor scoring system remains the universal standard for clinical applications<\/span>.<\/p>\n The SARC-F was originally developed and published in 2013<\/strong> by Theodore K. Malmstrom and John E. Morley in the Journal of the American Medical Directors Association<\/em> (JAMDA). The instrument was created as a public-domain clinical and research screening assessment. It is freely accessible for non-commercial academic research, public health surveillance, and clinical practice without licensing fees or royalty requirements. Commercial organizations incorporating the tool into proprietary software platforms or commercial clinical trials typically require attribution to the original authors and JAMDA publication.<\/p>\n Bahat, G., Yilmaz, O., Kiliç, C., Ören, M. M., & Karan, M. A. (2018). Performance of SARC-F in Regard to Sarcopenia Definitions, Muscle Mass and Functional Measures. The Journal of Nutrition, Health & Aging<\/em>, 22(8), 898–903. https:\/\/doi.org\/10.1007\/s12603-018-1067-8<\/a><\/p>\n Chen, L. K., Woo, J., Assantachai, P., Arai, H., Chou, M. Y., Chen, L. Y., Hsu, P. S., Lin, C. S., Lee, W. J., Lee, J. Y., & Morley, J. E. (2020). Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. Journal of the American Medical Directors Association<\/em>, 21(3), 300–307.e2. https:\/\/doi.org\/10.1016\/j.jamda.2019.12.012<\/a><\/p>\n Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., Schneider, S. M., Sieber, C. C., Topinkova, E., Vandewoude, M., Visser, M., & Zamboni, M. (2019). Sarcopenia: Revised European consensus on definition and diagnosis. Age and Ageing<\/em>, 48(1), 16–31. https:\/\/doi.org\/10.1093\/ageing\/afy169<\/a><\/p>\n Malmstrom, T. K., & Morley, J. E. (2013). SARC-F: A Simple Questionnaire to Rapidly Diagnose Sarcopenia. Journal of the American Medical Directors Association<\/em>, 14(8), 531–532. https:\/\/doi.org\/10.1016\/j.jamda.2013.05.018<\/a><\/p>\n Malmstrom, T. K., Miller, D. K., Simonsick, E. M., Ferrucci, L., & Morley, J. E. (2016). SARC-F: A Symptom Score to Predict Sarcopenia and Adverse Outcomes in the African American Health, Baltimore Longitudinal Study of Aging, and National Health and Nutrition Examination Survey Studies. Journal of the American Medical Directors Association<\/em>, 17(3), 275–280. https:\/\/doi.org\/10.1016\/j.jamda.2015.11.026<\/a><\/p>\n Verbrugge, L. M., & Jette, A. M. (1994). The disablement process. Social Science & Medicine<\/em>, 38(1), 1–14. https:\/\/doi.org\/10.1016\/0277-9536(94)90294-1<\/a><\/p>\n Visser, M., & Schaap, L. A. (2019). Nederlandse vertaling van de SARC-F vragenlijst voor sarcopenie screening. Tijdschrift voor Gerontologie en Geriatrie<\/em>, 50(4), 1–6.<\/p>\n2. Keywords<\/h2>\n
3. Authors<\/h2>\n
\n
\n
4. Purpose<\/h2>\n
5. Psychological Construct<\/h2>\n
\n
6. Theoretical Framework<\/h2>\n
7. Validity<\/h2>\n
Criterion and Construct Validity<\/h3>\n
\n
Convergent and Discriminant Validity<\/h3>\n
Predictive Validity<\/h3>\n
8. Reliability<\/h2>\n
\n
9. Factor Analysis<\/h2>\n
Exploratory Factor Analysis (EFA)<\/h3>\n
\n
Confirmatory Factor Analysis (CFA)<\/h3>\n
\n
10. Instrument \/ Measurement Tool<\/h2>\n
\n
\n
\n
11. Permissions & Fee and Test Year<\/h2>\n
12. References<\/h2>\n